Amplia Therapeutics Limited Overview
Amplia Therapeutics is a Melbourne-based, single-asset-centric oncology developer. Its lead asset is narmafotinib (AMP945), a highly selective oral inhibitor of focal adhesion kinase (FAK). FAK drives fibrotic stroma, immune suppression and drug-resistance signalling in solid tumours. Narmafotinib holds US FDA Orphan Drug and Fast Track designations in pancreatic cancer. In the single-arm Phase 1b/2a ACCENT trial it was combined with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic cancer. The combination produced a centrally reviewed objective response rate of 35.9%, a 7.8% complete response rate, median PFS of 7.7 months and median OS of 11.1 months, each numerically above the historical MPACT chemotherapy benchmark. The strategy is to make narmafotinib a "combination backbone": a registration path in pancreatic cancer (ACCENT Mini, then a Phase 2b/3), an ovarian cancer study with ANZGOG, and a KRAS-inhibitor combination in NSCLC with Eli Lilly. The company is funded by equity and the R&D Tax Incentive. It has no revenue and is roughly six quarters from needing new capital at current burn.
Company's own description (FY2026 Annual Report, Directors' Report)
The FY2026 directors' report gives the principal activity as developing two FAK-inhibiting drug candidates, narmafotinib (AMP945) and AMP886. According to the report, both compounds have strong potency and selectivity, good pharmacokinetics and drug-like properties, preclinical efficacy, and chemistry suited to manufacturing scale-up and long-term stability. The company is pursuing them across oncology (notably pancreatic cancer) and chronic fibrotic disease. The boilerplate "About Amplia" text calls the company an Australian pharmaceutical business advancing a pipeline of FAK inhibitors for cancer and fibrosis, with a focus on fibrotic cancers such as pancreatic and ovarian cancer.
Independent characterisation
| Revenue component (FY2026, AUD) | Amount | % of total |
|---|---|---|
| R&D Tax Incentive (refundable offset) | 4,778,235 | 87.0% |
| Interest income | 699,097 | 12.7% |
| Government grants | 12,000 | 0.2% |
| Other income | 1,000 | 0.0% |
| Total revenue and other income | 5,490,332 | 100% |
| Market | Size claimed (USD) | Basis |
|---|---|---|
| Pancreatic cancer | 2.5 billion | 2025, 7 major markets |
| Ovarian cancer | 3.9 billion | 2025, 7 major markets |
| Lung cancer | 32 billion | global |
| Colorectal cancer | 19 billion | global |
Amplia is a virtual, outsourced, clinical-stage small-molecule developer. Its value chain position is in-licensed discovery-stage IP taken through clinical development, with the aim of partnering or out-licensing before Phase 3 or commercialisation. The model is capital-light:
Discovery origin: the Cancer Therapeutics CRC (CTx), Melbourne. Intellectual property is in-licensed from Cancer Research Technology Ltd (CRT, now Cancer Research Horizons) under a March 2018 licence.
Manufacturing: outsourced to a contract development and manufacturing organisation. Laurus (India) is named for API manufacture.
Clinical execution: outsourced to CROs and hospital sites in Australia, South Korea and the US, plus investigator-initiated trials sponsored by cooperative groups (ANZGOG).
Partnering: non-exclusive clinical supply collaborations with large pharma (Eli Lilly, August 2026). These are not licensing deals.
Revenue model. There is currently no product, service, subscription or licensing revenue. The mix is:
Source: FY2026 consolidated statement of profit or loss.
Prospective revenue model. The intended route to value is one or more of the following:
-
out-licensing or co-development of narmafotinib with a pharma partner, earning upfront, milestone and royalty payments;
-
acquisition of the company;
-
less likely given its scale, eventual direct commercialisation in orphan pancreatic cancer.
Royalty obligations upstream reduce net economics. Milestones are owed to CRT and the Garvan Institute, and a legacy 3.25% royalty is owed to the original MIS416 vendors on any MIS416 revenues (that legacy asset is dormant).
Customer types and end-markets (prospective). The ultimate payers would be oncology prescribers and health systems. The commercial counterparties would be large and mid-cap pharma companies. End-markets per the company's September 2026 presentation, citing Clarivate / Nature Reviews Drug Discovery 2026 and Fortune Business Insights:
Strategy
Stated strategy (paraphrased themes, FY2026 Annual Report and September 2026 deck)
-
Advance narmafotinib to registration in first-line pancreatic cancer. A three-part FDA-aligned pathway: ACCENT Mini (daily dosing, two dose levels), then a randomised Phase 2b two-dose comparison under Project Optimus, then a pivotal Phase 3 against gemcitabine/nab-paclitaxel.
-
Position narmafotinib as a "versatile combination agent". Pair it with less toxic chemotherapy backbones and with targeted agents, particularly KRAS inhibitors, rather than with intensive regimens. This was reinforced by the AMPLICITY halt.
-
Expand into further fibrotic, FAK-high tumours. Ovarian cancer (PRROSE) and NSCLC (Lilly).
-
Build CMC and regulatory readiness. Commercial-scale API, automated capsule manufacture, FDA engagement.
-
Strengthen IP and pipeline depth. Crystal-form patent to at least 2040; new chemical entity filings to about 2046; AMP886.
-
Broaden the investor base. OTCQB quotation, US IR, investor conferences.
-
Business development. The Chair noted that talks with selected developers of KRAS inhibitors and other agents are under way. The Lilly agreement is the first public result.
Strategic initiatives in the last 24 months (October 2024 to October 2026)
| Initiative | Date | Description / target |
|---|---|---|
| AMPLICITY (narmafotinib + mFOLFIRINOX) | Ethics approval Jun–Jul 2025; first patient Sep 2025; halted Apr 2026 | US-oriented second backbone; abandoned after chemotherapy toxicity |
| A$27.5m capital raise | Jul–Sep 2025 | Stated to fund clinical activities "through 2027" |
| OTCQB quotation | Oct 2025 | US investor access |
| US presence expansion | Oct 2025 | ASX headline; specifics not disclosed |
| Next & Bio second agreement (Korea) | Dec 2025 | Patient-derived model screening of FAK plus KRAS-inhibitor combinations |
| Commercial-scale GMP manufacture | Jan 2026 | About 13 kg API |
| ACCENT Mini | Announced 19 May 2026; first dosing targeted Sep 2026 | 12 patients; safety/PK by Q1 2027 |
| PRROSE (ANZGOG) | Announced 8 May 2026; protocol 15 Sep 2026 | About 26 patients; sites by end-2026 |
| Board renewal | Jun–Jul 2026 | New Chair; Carter appointed |
| New-chemical-entity patent application | Jul 2026 | Potential protection to 2046 |
| Lilly clinical collaboration | 4 Aug 2026 | Phase 1b/2b, about 60 patients, starting late 2026; Amplia-funded |
Cost programmes: none announced. Resources were explicitly redeployed from AMPLICITY to ACCENT Mini.
ESG commitments: none formally announced.
Management guidance and targets
- No financial guidance is given (normal for a pre-revenue biotech).
Operational timeline guidance (September 2026 deck): ACCENT Mini safety/PK review complete Q1 2027; FDA meeting Q2 2027; ACCENT Reg Phase 2b start 2H 2027; PRROSE recruitment before end-2026; Lilly NSCLC study start late 2026.
- The June 2026 Appendix 4C mentions a "planned registrational submission to the FDA in Q2 2027". In context this means submitting the registrational protocol and package for the Phase 2b/3, not a marketing application.
Products & Services
Amplia has no marketed products. The catalogue below is the full disclosed development pipeline, grouped under the single segment.
Narmafotinib (AMP945): lead asset
| Programme | Indication / line | Combination | Design | Status (Oct 2026) |
|---|---|---|---|---|
| ACCENT | 1L metastatic pancreatic ductal adenocarcinoma (PDAC) | Gemcitabine + nab-paclitaxel (Abraxane®) | Phase 1b/2a, single-arm, Simon two-stage; 7 sites in Australia, 5 in Korea; 64 patients at top dose | Enrolment complete; company expected completion in Q3 CY2026 |
| AMPLICITY | 1L metastatic PDAC | Modified FOLFIRINOX | Phase 1b/2a under US IND; 2 Australian and 2 US sites open | Recruitment halted 7 Apr 2026 after 3 chemotherapy-related DLTs in 8 patients; 5 remain on treatment |
| ACCENT Mini (registration stage 1) | 1L advanced PDAC | Gemcitabine + Abraxane, daily narmafotinib | 12 patients, 2 dose cohorts, 3–4 Australian sites | First patient dosing targeted September 2026; safety/PK review Q1 2027 |
| ACCENT Reg Phase 2b | 1L advanced PDAC | Gemcitabine + Abraxane | Randomised two-dose comparison (FDA Project Optimus) | FDA meeting planned Q2 2027; start 2H 2027 |
| ACCENT Reg Phase 3 | 1L advanced PDAC | Gemcitabine + Abraxane vs chemotherapy alone | Pivotal, controlled | In planning; partner and financing not secured |
| PRROSE | High-grade serous ovarian cancer (poor responders before interval debulking surgery) | Carboplatin + paclitaxel | Investigator-initiated Phase 2, ANZGOG-sponsored; about 26 patients in Australia and New Zealand (15–20 in the May 2026 release) | Protocol finalised 15 Sep 2026; site activation targeted before end-2026 |
| Lilly collaboration | 2L KRAS G12C-mutant NSCLC | Olomorasib (Lilly, supplied in kind) | Phase 1b/2b: about 20 patients in dose escalation plus about 40 in a randomised two-dose comparison; Australia and US | Planned start late 2026; Amplia sponsors and funds; non-exclusive |
| KRAS-inhibitor combination 2 | — | Undisclosed KRAS inhibitor | Shown on the September 2026 timeline | Unconfirmed / pre-announcement |
| Endpoint | ACCENT (narmafotinib + gem/nab-pac) | MPACT (gem/nab-pac, historical) | Source |
|---|---|---|---|
| Objective response rate (confirmed) | 35.9% (23/64) | about 23% | FY2026 AR |
| ORR including unconfirmed responses | 42% | — | Jun-2026 Appendix 4C |
| Complete response rate | 7.8% (5/64), plus 1 pathological CR | about 0.2% (company figure) | FY2026 AR; Sep-2026 deck |
| Disease control rate | 70% | 50% | Jun-2026 Appendix 4C |
| Median PFS | 7.7 months | about 5.5 months | FY2026 AR |
| Median OS | 11.1 months | 8.5 months | FY2026 AR; Sep-2026 deck |
| Added toxicity | No significant additional burden; main narmafotinib-related adverse events were nausea, vomiting and diarrhoea | — | Sep-2026 deck |
Description: oral, highly potent and selective small-molecule FAK (PTK2) inhibitor. It is positioned as acting on three fronts: breaking down tumour fibrosis to improve drug penetration, relieving immune suppression, and blocking survival and resistance signalling in cancer cells.
Origin and IP: discovered at the Cancer Therapeutics CRC and in-licensed from CRT. INN approved June 2023. A crystalline salt-form patent (granted US, December 2025; also allowed or granted in Australia, Japan, Europe, India, Korea, Singapore and New Zealand) extends protection to at least 2040.
Regulatory status: FDA Orphan Drug Designation (pancreatic cancer, by FY2022); FDA Fast Track (advanced pancreatic cancer, 19 Sep 2024); open US IND (January 2024).
Formulation and dosing: oral capsules. ACCENT used an intermittent schedule (dosing on 12 of each 28-day cycle, per the June 2026 Appendix 4C). The Phase 1b recommended dose was reported as 400 mg in the FY2024 AR. Daily dosing at two dose levels is now under study.
Manufacturing: about 13 kg GMP API produced in early 2026 at a CDMO (Laurus, India), described as roughly one-tenth of anticipated commercial scale. Automated capsule manufacture is in development.
Pricing model: not applicable or not disclosed. As a reference point, the company deck cites gemcitabine plus Abraxane at about US$6,500–7,500 per month and NALIRIFOX at about US$13,610 per month.
ACCENT efficacy versus the MPACT historical benchmark (centrally reviewed, data to mid-March 2026):
Analyst note: these are cross-trial comparisons of a single-arm study against a historical control. They are hypothesis-generating, not registrational. The FDA has required a controlled comparison for approval, as the CEO acknowledged in the FY2026 letter.
AMP886: second candidate
Description: multi-kinase inhibitor of FAK, VEGFR3 and FLT3.
Stage: preclinical, targeting solid tumours.
Licence status: CRT extended the IND/Phase 1 deadline to 31 Dec 2023 (FY2022 AR). Current diligence status versus the licence is not publicly disclosed.
Target customer: prospective pharma partner.
Novel FAK-inhibitor series (new chemical entities)
Description: chemically novel compounds closely related to narmafotinib. A patent application was published in July 2026, with potential protection to 2046 if granted.
Stage: discovery / preclinical.
Fibrotic disease programmes
- Idiopathic pulmonary fibrosis (IPF) and other fibrotic disease: listed in the pipeline. A Phase 2 IPF trial was planned for 2H 2022 (FY2022 AR) but has not been initiated, and current status is not disclosed. Chronic toxicology studies to support IPF dosing were run in 2022.
Topical scar reduction / wound healing: a topical formulation of FAK inhibitors developed with CSIRO under an AusIndustry Entrepreneurs' Programme grant (May 2023). The pipeline showed it at "proof of concept developed" in FY2024. No clinical plans are disclosed.
Legacy asset
MIS416: (immunomodulator microparticle, from Innate): discontinued after the 2017 MS failure. A 3.25% royalty on any MIS416 revenues for radiation injury remains payable to the original vendors. The asset is commercially dormant.
Financial Narrative
All figures are AUD millions unless stated. They come from the audited consolidated statements in the FY2022, FY2024 and FY2026 Annual Reports; FY2023 comparatives are from the FY2024 AR and FY2025 comparatives from the FY2026 AR. Rows marked "derived" are analyst calculations from those statements. Product revenue was zero in every year.
Income statement
Margins. Gross, operating, EBITDA and net margins are n.m. because there is no product revenue. Measured against "revenue and other income", the FY2026 net loss equals -140% of that line. That ratio has no economic meaning and is shown only for completeness.
Revenue CAGR. On total revenue and other income, FY2022 to FY2026 compounds at about 29.0% a year (A$1.98m to A$5.49m). This reflects a rising R&D-incentive claim on rising R&D spend plus higher interest income on larger cash balances. It is not commercial growth.
Commentary.
Trend: R&D expense rose every year (+24% in FY2023, +24% in FY2024, +30% in FY2025, +21% in FY2026) as the company moved from a healthy-volunteer study to a multi-country Phase 2 programme, GMP scale-up and a second trial.
FY2024 inflection: the net loss fell 28% in FY2024 despite higher R&D. A catch-up of R&D-incentive income (A$4.44m against A$1.15m in FY2023) made the R&D-incentive share of R&D spend jump to 76%. This flatters the FY2024 loss and should be treated as a timing effect.
FY2026 drivers: the loss widened 17% to A$7.71m. The causes were R&D of A$9.08m (ACCENT completion, AMPLICITY start-up, CMC scale-up), administrative costs up 31% (US capital-markets presence, OTCQB, investor relations, board renewal) and patent costs up 83% (prosecution of the crystal-form and new-chemical-entity families). Interest income of A$0.70m (2.5 times FY2025) partly offset these increases, reflecting the larger post-placement cash balance.
Per-share losses: fell to -1.64c in FY2026 because weighted shares rose sharply after the July–September 2025 raisings. This is dilution, not efficiency.
Balance sheet
Commentary.
Balance-sheet troughs: FY2024 was the trough. Cash fell to A$3.39m and the company relied on a director loan (A$1.47m from Dr Peach at 10% simple interest) and an underwritten rights issue to stay funded.
Repair: the A$27.5m raise in July–September 2025 fully repaired the balance sheet, leaving A$27.85m cash and nil borrowings at 31 March 2026.
Accumulated losses: of A$152.8m mostly reflect the Innate/MIS416 era. Losses under the Amplia strategy (FY2019 to FY2026) total roughly A$34m.
Intangible: the A$7.94m licence intangible is carried at its 2018 deemed acquisition cost and is not amortised (not yet ready for use). It is tested for impairment annually as a key audit matter.
Cash flow
Commentary. Operating cash burn roughly doubled from A$4.4m (FY2022) to A$8.7m (FY2026). Capital spending is negligible because the model is virtual. Gross equity raised over five years totals about A$61.5m, against roughly A$30.4m of cumulative operating outflow.
The Q1 FY2027 (June 2026 quarter) Appendix 4C shows A$3.87m net operating outflow (R&D A$2.95m, staff A$0.46m, administration A$0.68m, interest received A$0.22m) and closing cash of A$23.98m. The company estimates 6.2 quarters of funding.
There is a data conflict here. The same Appendix 4C text describes the March 2026 quarter as A$3.5m of operating "inflows", whereas InvestSMART's summary of the March 4C reports A$3.5m of net outflows. The movement in cash from A$31.5m (December 2025) to A$27.9m (March 2026) supports an outflow, so the "inflows" wording is likely a drafting error.
An FY2026 R&D-incentive receivable of A$4.78m should be collected in roughly Q2–Q3 FY2027, following the pattern of October 2025, which would extend runway.
Ratios
The following ratios are n.m.: ROIC (negative operating returns on a non-earning intangible base), net debt / EBITDA (net cash and negative EBITDA), interest coverage (negative EBIT), and the cash conversion cycle (no inventory or trade receivables).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Jurisdiction | Function | Status |
|---|---|---|---|
Amplia Therapeutics Limited | Australia | Listed parent; R&D sponsor | Active |
ACN 612 556 948 Pty Ltd (formerly Amplia Therapeutics Pty Ltd) | Australia | Licence-holding company for AMP945/AMP886 | 100% owned |
Amplia Therapeutics (UK) Limited | United Kingdom | Dormant R&D vehicle | Deregistered 15 Mar 2022 |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Revenue and other income, single segment (AUD Mn) | 4.60 | 4.06 | 5.49 |
Loss before income tax, single segment (AUD Mn) | -4.50 | -6.57 | -7.71 |
YoY change in revenue and other income (%) | 257.3 | -11.7 | 35.2 |
Share of group revenue (%) | 100 | 100 | 100 |
Income Statement
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Product revenue (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
R&D tax incentive income (AUD Mn) | 1.98 | 1.15 | 4.44 | 3.77 | 4.78 |
Interest income (AUD Mn) | 0.00 | 0.10 | 0.15 | 0.28 | 0.70 |
Government grants and other (AUD Mn) | 0.00 | 0.04 | 0.02 | 0.01 | 0.01 |
Total revenue and other income (AUD Mn) | 1.98 | 1.29 | 4.60 | 4.06 | 5.49 |
Gross profit (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
R&D expense (AUD Mn) | 3.77 | 4.69 | 5.80 | 7.53 | 9.08 |
Patent and associated expense (AUD Mn) | 0.15 | 0.31 | 0.44 | 0.21 | 0.39 |
Administrative and general expense (AUD Mn) | 1.64 | 2.20 | 2.60 | 2.67 | 3.49 |
Share-based compensation (AUD Mn) | 0.06 | 0.21 | 0.09 | 0.08 | 0.13 |
Depreciation and amortisation (AUD Mn) | 0.00 | 0.07 | 0.09 | 0.09 | 0.09 |
Total operating expenses (AUD Mn) | 5.63 | 7.48 | 9.02 | 10.58 | 13.18 |
Operating deficit before financing (AUD Mn) | -3.64 | -6.19 | -4.42 | -6.52 | -7.69 |
EBITDA excl. interest income, derived (AUD Mn) | -3.64 | -6.21 | -4.48 | -6.71 | -8.30 |
Interest expense (AUD Mn) | 0.00 | 0.05 | 0.08 | 0.06 | 0.02 |
Pre-tax loss (AUD Mn) | -3.64 | -6.24 | -4.50 | -6.57 | -7.71 |
Income tax (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Net loss (AUD Mn) | -3.64 | -6.24 | -4.50 | -6.57 | -7.71 |
EPS basic, AUD cents | -2.50 | -3.22 | -2.32 | -2.14 | -1.64 |
EPS diluted, AUD cents | -2.50 | -3.22 | -2.32 | -2.14 | -1.64 |
Dividends per share, AUD cents | 0 | 0 | 0 | 0 | 0 |
R&D expense as % of total opex, derived | 67.0 | 62.7 | 64.3 | 71.2 | 68.9 |
R&D tax incentive as % of R&D expense, derived | 52.6 | 24.5 | 76.4 | 50.1 | 52.6 |
Balance Sheet and Share Count (millions)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and equivalents (AUD Mn) | 14.61 | 9.26 | 3.39 | 10.86 | 27.85 |
R&D tax incentive receivable (AUD Mn) | 1.84 | 1.15 | 3.18 | 3.77 | 4.78 |
Total current assets (AUD Mn) | 16.53 | 10.51 | 6.75 | 14.93 | 33.04 |
Intangibles: AMP945/AMP886 licence (AUD Mn) | 7.94 | 7.94 | 7.94 | 7.94 | 7.94 |
Goodwill (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Total assets (AUD Mn) | 24.48 | 18.68 | 14.85 | 22.94 | 41.44 |
Short-term borrowings (AUD Mn) | 0.00 | 2.11 | 1.49 | 0.00 | 0.00 |
Long-term borrowings (AUD Mn) | 2.10 | 0.00 | 0.00 | 0.00 | 0.00 |
Lease liabilities, current + non-current (AUD Mn) | 0.00 | 0.17 | 0.09 | 0.01 | 0.34 |
Total debt incl. leases, derived (AUD Mn) | 2.10 | 2.28 | 1.59 | 0.01 | 0.34 |
Net debt (negative = net cash), derived (AUD Mn) | -12.51 | -6.98 | -1.80 | -10.85 | -27.51 |
Total current liabilities (AUD Mn) | 0.53 | 2.75 | 3.40 | 1.89 | 1.67 |
Total liabilities (AUD Mn) | 2.64 | 2.85 | 3.43 | 1.91 | 1.97 |
Total equity (AUD Mn) | 21.85 | 15.84 | 11.42 | 21.02 | 39.47 |
Working capital, derived (AUD Mn) | 16.00 | 7.76 | 3.35 | 13.04 | 31.37 |
Issued capital (AUD Mn) | 151.51 | 151.53 | 151.53 | 167.39 | 193.43 |
Accumulated losses (AUD Mn) | -128.62 | -134.72 | -139.01 | -145.54 | -152.83 |
Shares on issue at year end (millions) | 193.85 | 194.01 | 194.01 | 387.95 | 513.07 |
NTA per share, AUD cents | 7.2 | 4.1 | 1.8 | 3.4 | 6.1 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
R&D tax incentive cash received (AUD Mn) | 1.14 | 1.84 | 2.41 | 3.18 | 3.77 |
Payments to suppliers (AUD Mn) | -4.59 | -6.06 | -6.18 | -9.10 | -11.58 |
Payments to employees (AUD Mn) | -0.95 | -1.20 | -1.53 | -1.22 | -1.61 |
Operating cash flow (AUD Mn) | -4.40 | -5.29 | -5.13 | -6.89 | -8.73 |
Capex: property, plant and equipment (AUD Mn) | -0.01 | -0.02 | -0.00 | -0.00 | -0.03 |
Free cash flow, derived (AUD Mn) | -4.42 | -5.31 | -5.13 | -6.89 | -8.77 |
Gross equity proceeds incl. options (AUD Mn) | 16.27 | 0.02 | 0.00 | 17.28 | 27.88 |
Capital-raising costs (AUD Mn) | -1.18 | 0.00 | 0.00 | -1.33 | -1.86 |
Borrowings drawn (AUD Mn) | 2.10 | 0.00 | 1.47 | 0.00 | 0.00 |
Borrowings repaid (AUD Mn) | 0.00 | 0.00 | -2.10 | -1.47 | 0.00 |
Net financing cash flow (AUD Mn) | 17.19 | -0.08 | -0.77 | 14.32 | 25.94 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on average equity, derived (%) | -22.6 | -33.1 | -33.0 | -40.5 | -25.5 |
ROA on average assets, derived (%) | -20.6 | -28.9 | -26.9 | -34.8 | -23.9 |
Current ratio, derived (x) | 31.2 | 3.8 | 2.0 | 7.9 | 19.8 |
Debt to equity incl. leases, derived (x) | 0.10 | 0.14 | 0.14 | 0.00 | 0.01 |
Asset turnover on revenue and other income, derived (x) | 0.11 | 0.06 | 0.27 | 0.21 | 0.17 |
Cash runway at FY-end operating burn, derived (years) | 3.3 | 1.7 | 0.7 | 1.6 | 3.2 |
Revenue by Region and Region Margins & Growth (%)
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia: revenue and other income (AUD Mn) | 4.60 | 4.06 | 5.49 |
Americas: revenue (AUD Mn) | 0 | 0 | 0 |
EMEA: revenue (AUD Mn) | 0 | 0 | 0 |
APAC ex-Australia: revenue (AUD Mn) | 0 | 0 | 0 |
Australia YoY growth (%) | 257.3 | -11.7 | 35.2 |
Per-Share Data and Share Count (millions)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at 31 March (AUD cents) | 14.5 | 8.5 | 7.0 | 7.0 | 23.5 |
Shares on issue at 31 March (millions) | 193.85 | 194.01 | 194.01 | 387.95 | 513.07 |
Market cap at 31 March, derived (AUD Mn) | 28.1 | 16.5 | 13.6 | 27.2 | 120.6 |
Net cash at 31 March, derived (AUD Mn) | 12.5 | 7.0 | 1.8 | 10.8 | 27.5 |
Enterprise value at 31 March, derived (AUD Mn) | 15.6 | 9.5 | 11.8 | 16.4 | 93.1 |
Valuation Multiples
| Multiple | Amplia | Comment |
|---|---|---|
EV/Sales | About 6.9x on "revenue and other income" | n.m. economically (R&D-incentive income) |
P/B | About 1.56x (A$61.6m / A$39.47m equity at 31 Mar 2026) | Book is mainly cash plus the A$7.9m licence |
Market cap / cash | About 2.6x (vs A$24.0m at 30 Jun 2026) | The market assigns about A$38m EV to the pipeline |
Raising by Period
| Period | Raising |
|---|---|
FY2022 | A$16.27m |
FY2024 (closed May 2024) | A$4.27m entitlement offer at about 5.5c |
FY2026 | A$27.88m (placement at 23c, SPP at 18c, options) |
Analyst Conclusions
Management guidance (operational; no financial guidance)
| Item | Expected timing |
|---|---|
| ACCENT Mini first dosing | September 2026 |
| ACCENT Mini safety/PK review | Q1 2027 |
| FDA meeting on the registrational Phase 2b design | Q2 2027 |
| Registrational Phase 2b start | 2H 2027 |
| PRROSE site activation and recruitment | Before end-2026 |
| Lilly NSCLC Phase 1b/2b start | Late 2026 |
| Mature AMPLICITY data on the 5 remaining patients | "In due course" |
| Second KRAS-inhibitor combination | On the timeline; undisclosed |
Consensus growth expectations
No meaningful revenue or earnings consensus exists. The single published broker target (A$0.42, Bell Potter, pre-April 2026) implies a large perceived discount to risk-adjusted pipeline value, but it predates the AMPLICITY halt.
Bull case
-
Clinically differentiated signal. A 7.8% CR rate and more than two months of mOS/mPFS improvement over MPACT, with no added toxicity, is rare in 1L metastatic PDAC. Daily dosing (ACCENT Mini) could deepen the effect.
-
Optionality in the KRAS era. Narmafotinib's resistance-blocking and stroma-remodelling mechanism suits combination with RAS inhibitors, a class with 80+ clinical assets and big-pharma sponsors. Lilly's in-kind collaboration is early validation and could lead to a licensing or M&A event.
-
Asymmetric valuation. An EV of about A$38m (September 2026) for a Fast Track / Orphan asset with FDA-aligned dose optimisation, IP to 2040+, GMP scale-up done and three trials starting looks inexpensive if any study reads out positively.
Bear case
-
Evidence quality. Single-arm ACCENT data against historical controls often overstate benefit, and the 2.6-month mOS improvement may shrink or vanish in a randomised trial.
-
Shrinking addressable backbone. AMPLICITY showed narmafotinib cannot readily be escalated on mFOLFIRINOX (the dominant US/EU fit-patient regimen), and RAS inhibitors may push chemotherapy-centric 1L regimens aside before a Phase 3 could read out around 2029 or later.
-
Funding and dilution. At about A$15.5m annualised burn (Q1 FY2027 run-rate) against A$24m cash plus about A$4.8m R&D refund, a raise is likely in CY2027, possibly at depressed prices. A Phase 3 is not fundable on a standalone basis.
Key catalysts and monitorables (next 12 months)
| Expected timing | Catalyst / monitorable | Why it matters |
|---|---|---|
| Late Oct 2026 | Sep-2026 quarter Appendix 4C | Burn rate; confirmation of ACCENT Mini dosing; FY2026 R&D refund timing |
| Q4 2026 | FY2026 R&D Tax Incentive refund (about A$4.8m) | Runway extension |
| Q4 2026 | PRROSE ethics approval and first patient | Second indication |
| Late 2026 | Lilly NSCLC study first patient | KRAS thesis execution |
| 26 Nov 2026 | Half-year report H1 FY2027 | Financials; going-concern language |
| H2 2026 / 2027 | Final ACCENT dataset (trial completion) and any publication | Durability and OS maturity |
| Q1 2027 | ACCENT Mini safety/PK readout | Daily-dose tolerability; whether the dose-comparison design holds |
| Q2 2027 | FDA meeting on the registrational Phase 2b | Regulatory path clarity |
| 2,027 | Capital raise and/or partnering announcement | Funding of the Phase 2b/3 |
| Ongoing | Second KRAS-inhibitor collaboration; options overhang (A$0.17, October 2027 expiry) | BD momentum; dilution |
Analyst verdict
Amplia Therapeutics is now a credible, if still speculative, single-asset oncology developer. Narmafotinib has delivered one of the more interesting signals in first-line metastatic pancreatic cancer in recent years. A centrally reviewed 35.9% ORR, a 7.8% complete-response rate and an 11.1-month median OS were achieved with an intermittent schedule and no meaningful added toxicity. The FDA has engaged constructively (Orphan, Fast Track, Type D alignment). Manufacturing is ready for later-stage trials. The Lilly collaboration, although economically thin, gives third-party validation of the KRAS-combination thesis that will probably decide narmafotinib's long-term relevance.
The case is held back by three facts. First, every efficacy comparison so far is against a historical benchmark. Second, the April 2026 AMPLICITY halt removed the FOLFIRINOX backbone and with it much of the near-term US/EU commercial logic. Third, the balance sheet (A$24.0m, about six quarters of runway at the June 2026 burn) can fund dose optimisation and proof-of-concept studies but not a pivotal trial. The market's verdict is visible in the price: from about A$0.265 after the March 2026 data, the stock fell to about A$0.12 by mid-September, valuing the pipeline at roughly A$38m of enterprise value.
On balance, we see Amplia as a high-risk, catalyst-driven holding whose value depends on two things. One is converting the ACCENT signal into a partnered, randomised Phase 2b. The other is producing clinical evidence that narmafotinib improves KRAS-inhibitor outcomes. If the 2027 milestones arrive on time (ACCENT Mini safety, the FDA meeting, early Lilly-combination data), today's valuation is likely to prove too low. If a non-dilutive or partner-funded route to Phase 3 does not emerge, dilution will continue to cap returns. Position sizing should reflect binary clinical and financing risk. Rating framework: Speculative / High Risk; monitor the Q4 CY2026 to Q2 CY2027 catalysts.
Data-integrity notes
-
All financial figures are from audited annual reports (FY2022, FY2024 and FY2026, including comparatives) unless marked "derived" (analyst calculation) or attributed to secondary sources.
-
Conflicts noted:
-
Platinum's stake is quoted at 9.31% in its notice versus about 8.8% on the current share count.
-
The June 2026 Appendix 4C describes the March 2026 quarter as operating "inflows", inconsistent with the cash movement and the March 4C summary.
-
PRROSE enrolment is about 26 in the Sept 2026 release versus 15–20 in the May 2026 release.
-
A secondary article claiming a 76% share-price surge in late May 2026 is inconsistent with exchange price data (about A$0.13–0.15 in late May 2026) and has been disregarded.
-
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background | Education | Age |
|---|---|---|---|---|---|
Jane Bell AM | Independent NED; Chair since 30 Jun 2026; Chair of Audit & Risk Committee (pre-transition) | 12 Apr 2021 | Banking and finance lawyer; NED since 2002 on 17 boards; Deputy Chair of Monash Health; director of Mesoblast (ASX: MSB / Nasdaq: MESO); former Chair of Royal Melbourne Hospital and BioMedVic; AM 2023 | BEc (Monash), LLB (Melbourne), LLM (King's College London), FAICD | — |
Dr Warwick Tong | Non-Executive Director (Chair 25 May 2018 to 30 Jun 2026) | 4 May 2018 | Physician; Glaxo, GlaxoWellcome, GSK, Surface Logix; CEO of the Cancer Therapeutics CRC 2011 to April 2018 (originator of Amplia's assets); director of Aculeus, Clear Scientific and Pacalis | MB ChB (Auckland), MPP (Victoria University of Wellington), GAICD | — |
Dr Robert Peach | Independent NED; Chair of Remuneration & Nomination Committee | 2 Sep 2015 | Co-founder and CSO of Receptos (acquired by Celgene for US$7.8bn, 2015); Biogen Idec, IDEC, BMS; director of Rekover Therapeutics | PhD (Otago; also Canterbury) | 70 (MarketScreener) |
Brett Carter | Non-Executive Director | Early July 2026 | 25+ years in oncology development and business development; 8 years in GSK global corporate transactions; former CEO of Cancer Therapeutics CRC | — | — |
Dr Christopher Burns | CEO and Managing Director | NED 4 May 2018; CEO/MD 5 Dec 2022 | Medicinal chemist; Pfizer UK; Cytopia Research Director (co-discovery of momelotinib, FDA-approved 2023); WEHI Laboratory Head; Certa, MycRx; inventor on 30+ patents; co-recipient of the 2024 Prime Minister's Prize for Innovation | BSc (Hons), PhD (Melbourne), FRACI, FRSC, FAHMS, GAICD | — |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Title | Since | Prior roles |
|---|---|---|---|
Dr Christopher Burns | CEO and MD | 5 Dec 2022 | See above |
Hamish George | CFO | 25 Feb 2026 (also CFO from 1 Oct 2021 to 2023 via Bio101) | Bio101 Financial Advisory; BCom MA CA |
Dr Rhiannon Jones | COO | Not disclosed (in role by FY2024) | Cancer Therapeutics CRC; PhD GAICD |
Dr Jason Lickliter | Chief Medical Officer | 12 May 2025 (clinical adviser since 2021) | Medical oncologist and clinical triallist (Nucleus Network per deck); MBBS FRACP |
Jonathan Barlow | Head of Business Development | — | Telix Pharmaceuticals; LLB BSc GDipBA GAICD |
Andrew J. Cooke | Company Secretary | 11 Oct 2013 | Lawyer, corporate finance and governance; LLB (Sydney) |
“—” = not publicly disclosed.
Directors' Remuneration
| Person | Cash salary/fees | Cash bonus | Superannuation | Share-based (options) | Total FY2026 | Total FY2025 |
|---|---|---|---|---|---|---|
Warwick Tong (Chair) | 70,000 | 0 | 0 | 27,856 | 97,856 | 70,000 |
Robert Peach | 50,000 | 0 | 0 | 19,897 | 69,897 | 50,000 |
Jane Bell | 44,643 | 0 | 5,357 | 19,897 | 69,897 | 50,000 |
Christopher Burns (CEO/MD) | 320,017 | 0 | 29,983 | 27,481 | 377,481 | 466,222 |
Total KMP | 484,660 | 0 | 35,340 | 95,131 | 615,131 | 636,222 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
12 May 2025 | Lickliter appointed CMO | Ahead of the registrational programme |
25 Feb 2026 | George replaces Luscombe as CFO | Not explained beyond the appointment |
30 Jun 2026 | Bell succeeds Tong as Chair | Board renewal and succession plan; Tong stays as NED |
Jul 2026 | Carter joins board | Adds global business-development and transactions expertise ahead of partnering |
Major Shareholders
| Holder | Shares | % of issued capital | Date / source |
|---|---|---|---|
Platinum Investment Management Ltd | 45,313,932 | 9.31% as notified (about 8.8% of the current 513.3m shares) | — |
Pengana Capital Group Ltd and subsidiaries | 27,544,919 | 5.37% | 22 Jun 2026 (FilingReader) |
Acorn Capital Ltd | — | Substantial (≥5%) per Sep-2026 deck | Company deck |
Blueflag Holdings Pty Ltd (Blueflag Trust) | — | Substantial (≥5%) per Sep-2026 deck | Company deck |
Directors' Shareholdings
| Director | Shares | Options (vested) |
|---|---|---|
Peach | 6,131,164 | 1,055,808 |
Burns | 4,155,574 | 3,207,869 |
Tong | 3,864,073 | 858,565 |
Bell | 3,661,751 | 762,329 |
Total | 17,812,562 (about 3.5% of shares) | — |
Competitive Landscape
Key Competitors
| # | Company | Relevant asset(s) | Overlap with Amplia | Status (as reported) |
|---|---|---|---|---|
| 1 | Verastem Oncology (US) | Defactinib (FAK) + avutometinib (RAF/MEK) | Closest FAK comparator; validates the class | FDA accelerated approval 2025 in KRAS-mutated recurrent low-grade serous ovarian cancer (Amplia FY2026 AR / Sep-2026 deck) |
| 2 | InxMed (China) | Ifebemtinib (FAK) | FAK plus KRAS combinations | Early clinical data published 2026 (Lancet Respiratory Medicine, per Amplia deck) |
| 3 | Revolution Medicines (US) | Daraxonrasib (RAS(ON) multi-selective) | Reshaping PDAC treatment; potential combination partner or substitute for chemotherapy | Amplia's September 2026 deck reports US approval in second-line advanced PDAC in August 2026 |
| 4 | Eli Lilly (US) | Olomorasib (KRAS G12C) plus G12D and pan-KRAS programmes | Partner, but also an independent PDAC/NSCLC developer | Two global Phase 3 trials in NSCLC; FDA Breakthrough Therapy for KRAS G12C PDAC (secondary report) |
| 5 | Amgen | Sotorasib (KRAS G12C) | Standard of care in KRAS G12C NSCLC | Approved |
| 6 | Bristol Myers Squibb (incl. Mirati) | Adagrasib (KRAS G12C); Abraxane (backbone) | Competitor and backbone owner | Approved |
| 7 | Ipsen | Onivyde (NALIRIFOX) | Competing 1L PDAC backbone (US-approved), described as less toxic than FOLFIRINOX | Approved (US) |
| 8 | Boehringer Ingelheim, Roche, Pfizer, J&J, Bayer, Astellas, Chugai, Erasca, BridgeBio and others | KRAS/RAS inhibitors (80+ in development per Amplia) | Competition for combination slots; also potential partners | Phase 1 to 3 |
| 9 | Generic gemcitabine; FOLFIRINOX components | Chemotherapy | The backbone narmafotinib must improve on | Generic |
| 10 | Other ASX small-cap oncology developers (e.g. Race Oncology, Kazia Therapeutics, Prescient Therapeutics) | Varied | Compete for the same ASX biotech capital | Clinical |
Peer Comparison FY2026
| Attribute | Amplia | Verastem (FAK peer) | Revolution Medicines (RAS peer) | Lilly (partner / competitor) |
|---|---|---|---|---|
Lead modality | Selective oral FAK inhibitor | FAK inhibitor + RAF/MEK | RAS(ON) inhibitor | KRAS G12C inhibitor |
Most advanced stage | Phase 1b/2a complete; registration path starting | Approved (LGSOC, 2025) | Approved per Amplia deck (2L PDAC, Aug 2026) | Phase 3 (olomorasib) |
Revenue | 0 | — | — | — |
Latest cash | A$24.0m (30 Jun 2026) | — | — | — |
R&D intensity | About 69% of opex | — | — | — |
Recent Developments
--



